Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Income: 2017-2025

Historic Operating Income for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Sep 2025 value amounting to -$142.6 million.

  • Crinetics Pharmaceuticals' Operating Income fell 62.40% to -$142.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$477.8 million, marking a year-over-year decrease of 55.77%. This contributed to the annual value of -$338.9 million for FY2024, which is 52.22% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Operating Income is -$142.6 million, which was down 10.44% from -$129.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Operating Income registered a high of -$22.9 million during Q1 2021, and its lowest value of -$142.6 million during Q3 2025.
  • For the 3-year period, Crinetics Pharmaceuticals' Operating Income averaged around -$85.9 million, with its median value being -$82.8 million (2024).
  • Data for Crinetics Pharmaceuticals' Operating Income shows a maximum YoY plummeted of 82.28% (in 2022) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Operating Income (Quarterly) stood at -$26.1 million in 2021, then slumped by 82.28% to -$47.6 million in 2022, then plummeted by 31.76% to -$62.7 million in 2023, then plummeted by 51.21% to -$94.7 million in 2024, then crashed by 62.40% to -$142.6 million in 2025.
  • Its Operating Income stands at -$142.6 million for Q3 2025, versus -$129.1 million for Q2 2025 and -$111.4 million for Q1 2025.